Johnson & Johnson ($JNJ) and Pharmacyclics ($PCYC) nabbed the FDA's new breakthrough designation for their cancer drug ibrutinib, a promising late-stage therapy that will be put in the hands of regulators later this year. Report
Download this free whitepaper to learn why key account management is so crucial to healthcare, and how to overcome common barriers to KAM. Review the skills every key account manager needs to know, as well as new rules, and tools for successful marketing and sales in the rapidly changing industry. Download here.
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 100,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!